Toll-like receptor 3 deficiency in autoimmune encephalitis post–herpes simplex encephalitis

Thaís Armangue, MD, PhD,* Benjamin J. Baucells, MD,* Alexandrue Viagea, MD, PhD,* Mar Petit-Pedrol, PhD, Ana Esteve-Sole, PhD, Angela Deya-Martínez, MD, PhD, Raquel Ruiz-García, MD, PhD, Manel Juan, MD, PhD, Rebeca Pérez de Diego, PhD, Josep Dalmau, MD, PhD, and Laia Alsina, MD, PhD

Neurol Neuroimmunol Neuroinflamm 2019;6:e611. doi:10.1212/NXI.0000000000000611

The Toll-like receptor 3 (TLR3) pathway is a key component of the innate immunity that prevents replication of viruses in the CNS. Inborn errors of this pathway (TLR3-pathway deficiency), which includes defects in the genes TLR3, UNC93B1, TRIF, TRAF3, TBK1 and IRF3, occur in 10% of patients with herpes simplex encephalitis (HSE),1,2 and about 66% of these patients develop relapses of HSE.1 A recent study showed that 27% of patients with HSE develop autoimmune encephalitis (AE) in the weeks or months ensuing the infection.3 It is unknown whether TLR3-pathway deficient patients can also develop AE post-HSE. Here we report a patient with TLR3-pathway deficiency who developed HSE and a relapse of the viral infection followed by AE post-HSE, highlighting the fact that TLR3-pathway deficient patients should be carefully followed for both HSE relapses and AE.

Case

A 6-year-old healthy Caucasian girl, with a family history of maternal grandfather with recurrent herpetic keratitis, developed acute-onset headache, fever, decreased level of consciousness, aphasia, and right hemiparesis. Brain MRI showed bilateral hemorrhagic temporal lesions leading to suspect HSE. Signs of cranial hypertension precluded CSF studies; however, a positive herpes simplex virus 1 (HSV-1) PCR was obtained in the blood samples. IV acyclovir resulted in symptom improvement, and 3 weeks later the patient was discharged home with residual aphasia.

Five months later, she was readmitted with severe headache and decreased level of consciousness. Brain CT showed new hemorrhagic temporal lesions. She required urgent decompressive craniectomy, and a brain tissue sample was HSV-1 PCR positive. Genetic studies showed that the patient and the mother carried a heterozygous missense mutation p.Glu110Lys (c.328G>A) in exon 2 of the gene TLR3 (NM_003265.2) (figure, A and B). Such mutation shows a very low allelic frequency (0.00082%, 1/121,316). Functional studies on patient’s fibroblasts (figure, C) and monocyte-derived dendritic cells showed a decrease in TLR3-mediated activation (methods in appendix e-1, links.lww.com/NXI/A141). The patient received a new 21-day course of IV acyclovir followed by oral valganciclovir.

One year later, 17 months after the initial episode of HSE, she developed behavioral changes characterized by aggressivity and paranoid thoughts. CSF studies showed pleocytosis (15 cells/μL) and elevated protein concentration (100 mg/dL) but were HSV-1 PCR negative. CSF immunohistochemistry studies on rat brain tissue (figure, D, upper panel) and cultured live neurons showed...
strong reactivity revealing the presence of neuronal antibodies. Autoantibodies against N-methyl-D-aspartate, γ-aminobutyric acid A, and other known receptors and cell surface proteins were all negative (methods in appendix e-1, links.lww.com/NXI/A141). The indicated patient’s antibodies were absent in samples of CSF obtained during HSE (data not shown). With the diagnosis of AE post-HSE, she was started on high-dose IV steroids and immunoglobulins without a clear improvement. Subsequently, rituximab (2 doses 500 mg/m² 2 weeks apart) resulted in neurologic improvement. A CSF sample obtained 4 months later was no longer reactive with brain.

**Discussion**

We report a young girl with recurrent HSE and a new TLR3 mutation associated with absent interferon-β responses to TLR3 agonist who several months after the first HSE episode developed recurrent HSE followed by AE. TLR3-pathway deficient patients, especially TLR3-deficient, are prone to develop HSE relapses, putting them at risk of developing AE. Indeed, a recent series of patients with HSE showed that 27% subsequently developed AE; none of them were investigated for TLR3-pathway deficiency but the current case indicates that patients with this deficiency are also at risk of AE. The symptoms of our patient (predominant behavioral abnormalities) are typical of AE post-HSE in patients older than 4 years, yet the long interval between HSE and AE (17 months since the onset of HSE and 12 months since the relapse of HSE) is somewhat atypical (median 26 days in children aged 4 years or younger and 43 days in patients older than 4 years), but similar prolonged intervals occurred in 7% of patients in a recently reported series. The exact mechanisms underlying this severe immune-mediated complication are unknown. It has been postulated that the neuronal destruction caused by the virus leads to a release of antigens, which in the context of severe inflammation results in neuronal autoimmunity, such as that shown in our patient. In
patients with TLR3-pathway deficiency, the increased number of episodes of HSE theoretically increases the risk of this autoimmune complication. Our case suggests that patients with recurrent HSE or family history of HSE or HSV keratitis should be assessed for TLR3-pathway deficiency.1,6,7 If the function of this pathway is impaired, patients should be carefully followed for potential relapses of HSE or AE post-HSE.

Acknowledgment
The authors thank Maria Rodés, Marta Muñoz, Mercè Alba, Eva Caballero, and Esther Aguilar for excellent administrative and technical support.

Study funding
This study was supported in part by Mutua Madrileña Foundation Award (AP162572016, T.A.); Plan Nacional de I+D+i and cofinanced by the ISCIII—Subdirección General de Evaluación y Formento de la Investigación Sanitaria—and the Fondo Europeo de Desarrollo Regional (ISCIII-FEDER; PI18-00486 to T.A.; 17/00234 to J.D.; PI15/01094, PPIS0200 (AC16/00025), and PI18/00223 to L.A.; PI14/00616 and PI17/00543 to R.P.d.D.); Pla estratègic de recerca i innovació en salut (PERIS), Departament de Salut, Generalitat de Catalunya (SLT006/17/00362 to T.A.; SLT006/17/00199 to L.A.); a 2017 Leonardo Grant for Researchers and Cultural Creators, BBVA Foundation to L.A.; Ramon Areces Foundation, through a grant from the XVII Concurso Nacional de Ayudas a la Investigación to L.A.; and Fundació CELLEX to J.D.

Disclosure
J. Dalmau holds patents for the use of Ma2, NMDAR, GABAβR, GABAαR, DPXX, and IgLON5 as autoantibody tests and receives royalties related to autoantibody tests from Athena Diagnostics and Euroimmun, Inc., and is editor of Neurology®: Neuroimmunology & Neuroinflammation. The other authors declare no conflict of interest related to this manuscript. Go to Neurology.org/NN for full disclosures.

Publication history
Received by Neurology: Neuroimmunology & Neuroinflammation June 21, 2019. Accepted in final form July 26, 2019.

Appendix

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Role</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexandru Viagea, MD, PhD</td>
<td>Hospital Sant Joan de Déu-Hospital Clinic Barcelona</td>
<td>Author</td>
<td>Performed the TLR3-pathway studies on dendritic cells and genetics, analyzed the data; drafted the manuscript; developed the figures</td>
</tr>
<tr>
<td>Mar Petit-Pedrol, PhD</td>
<td>IDIBAPS</td>
<td>Author</td>
<td>Performed the neuroimmunologic studies; analyzed the data; developed the figures; critical review of the manuscript</td>
</tr>
<tr>
<td>Ana Esteve-Solé, PhD</td>
<td>Sant Joan de Déu Research Institute and Hospital Sant Joan de Déu-Hospital Clinic Barcelona</td>
<td>Author</td>
<td>Performed the TLR3-pathway studies on dendritic cells, analyzed the data; critical review of the manuscript</td>
</tr>
<tr>
<td>Angela Deyà-Martinez, MD, PhD</td>
<td>Sant Joan de Déu Children's Hospital</td>
<td>Author</td>
<td>Follows the patient; analyzed the data; critical review of the manuscript</td>
</tr>
<tr>
<td>Raquel Ruiz-García, MD, PhD</td>
<td>Hospital Sant Joan de Déu-Hospital Clinic Barcelona</td>
<td>Author</td>
<td>Analyzed the data; critical review of the manuscript</td>
</tr>
<tr>
<td>Manel Juan, MD, PhD</td>
<td>Hospital Sant Joan de Déu-Hospital Clinic Barcelona</td>
<td>Author</td>
<td>Performed the TLR3-pathway studies on dendritic cells, analyzed the data; critical review of the manuscript</td>
</tr>
<tr>
<td>Rebeca Pérez de Diego, PhD</td>
<td>IdiPAZ Institute for Health Research</td>
<td>Author</td>
<td>Performed the TLR3-pathway studies on fibroblasts, analyzed the data; developed the figures; critical review of the manuscript</td>
</tr>
<tr>
<td>Josep Dalmau, MD, PhD</td>
<td>IDIBAPS, Hospital Clinic and University of Pennsylvania, Philadelphia</td>
<td>Author</td>
<td>Analyzed the data; critical review of the manuscript</td>
</tr>
<tr>
<td>Laia Alsina, MD, PhD</td>
<td>Sant Joan de Déu (SJ) Barcelona Children's Hospital and Hospital Sant Joan de Déu-Hospital Clinic</td>
<td>Author</td>
<td>Design and conceptualized study; analyzed the data; follow the patient; drafted the manuscript; developed the figures</td>
</tr>
</tbody>
</table>

References
Toll-like receptor 3 deficiency in autoimmune encephalitis post–herpes simplex encephalitis

Thaís Armangue, Benjamin J. Baucells, Alexandru Vlagea, et al.

Neurol Neuroimmunol Neuroinflamm 2019;6;
DOI 10.1212/NXI.0000000000000611

This information is current as of September 5, 2019